Compare HLN & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | SLRX |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 3.6M |
| IPO Year | N/A | N/A |
| Metric | HLN | SLRX |
|---|---|---|
| Price | $10.14 | $0.67 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.7M | 297.1K |
| Earning Date | 07-31-2025 | 11-14-2025 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 41.64 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $15,096,588,575.00 | N/A |
| Revenue This Year | $1.51 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $21.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.71 | $0.62 |
| 52 Week High | $11.42 | $108.00 |
| Indicator | HLN | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.58 | 26.00 |
| Support Level | $10.05 | $0.62 |
| Resistance Level | $10.16 | $0.72 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 94.78 | 7.14 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.